ERBB2 and breast cancer: In patients with HR+/HER2- BC, the confirmed ORR was 30.1% (95% CI, 21.8–39.4), the mPFS was 7.4 months (95% CI, 4.7–8.4) and the mOS was 14.6 months (95% CI, 11.3–19.5).